PRESS RELEASE

Q1 2025 — Press release

Q1 2025PDF · 13 pages359 KB
- 1 -
News Release
____________________________________________________________________________
Merck Announces First-Quarter 2025 Financial Results
- Total Worldwide Sales Were $15.5 Billion, a Decrease of 2% From First Quarter 2024;
Excluding the Impact of Foreign Exchange, Sales Grew 1%
o KEYTRUDA Sales Grew 4% to $7.2 Billion; Excluding the Impact of Foreign
Exchange, Sales Grew 6%
o WINREVAIR Sales Were $280 Million
o Animal Health Sales Grew 5% to $1.6 Billion; Excluding the Impact of Foreign
Exchange, Sales Grew 10%
o GARDASIL/GARDASIL 9 Sales Declined 41% to $1.3 Billion; Excluding the
Impact of Foreign Exchange, Sales Declined 40%
- GAAP EPS Was $2.01; Non-GAAP EPS Was $2.22
- Presented Compelling Data From a Diverse Range of Programs, Including:
o Phase 3 Trial of Subcutaneous Pembrolizumab With Berahyaluronidase Alfa
o Phase 3 ZENITH Trial of WINREVAIR for the Treatment of Adults With PAH
(WHO Group 1) Functional Class III or IV at High Risk of Mortality
o Phase 3 Trials Evaluating Investigational, Once-Daily, Oral Two-Drug Regimen
of Doravirine/Islatravir for the Treatment of Adults With Virologically Suppressed
HIV-1 Infection
- Expanded Pipeline Through Exclusive License Agreement With Hengrui Pharma for an
Investigational Oral Small Molecule Lp(a) Inhibitor; Transaction Expected to Close in
Second Quarter 2025
- Full-Year 2025 Financial Outlook
o Continues To Expect Worldwide Sales To Be Between $64.1 Billion and $65.6
Billion
o Now Expects Non-GAAP EPS To Be Between $8.82 and $8.97; Outlook Revised
to Reflect Negative Impact From Anticipated One-Time Charge of Approximately
$0.06 per Share Related to License Agreement With Hengrui Pharma
o Outlook Absorbs an Estimated $200 Million of Additional Costs for Tariffs
Implemented to Date
RAHWAY, N.J., April 24, 2025 – Merck (NYSE: MRK), known as MSD outside the United States
and Canada, today announced financial results for the first quarter of 2025.
“Our company made strong progress to start the year, with increasing contributions from
our newer commercialized medicines and vaccines and continued advancement of our
pipeline,” said Robert M. Davis, chairman and chief executive officer, Merck. “We are working
with focus and urgency to both realize the full potential of our near-term opportunities and to

-- 1 of 13 --

- 2 -
rapidly progress the next wave of innovation that will positively impact the lives of patients and
drive future value creation for all of our stakeholders.”
Financial Summary
$ in millions, except EPS amounts
First Quarter
2025 2024 Change
Change Ex-
Exchange
Sales $15,529 $15,775 -2% 1%
GAAP net income1 5,079 4,762 7% 12%
Non-GAAP net income that excludes certain items1,2* 5,611 5,279 6% 11%
GAAP EPS 2.01 1.87 7% 13%
Non-GAAP EPS that excludes certain items2* 2.22 2.07 7% 12%
*Refer to table on page 7.
For the first quarter of 2025, Generally Accepted Accounting Principles (GAAP) earnings
per share (EPS) assuming dilution was $2.01 and non-GAAP EPS was $2.22. GAAP and non-
GAAP EPS in the first quarter of 2024 include a charge of $0.26 per share for the acquisition of
Harpoon Therapeutics, Inc. (Harpoon).
Non-GAAP EPS excludes acquisition- and divestiture-related costs, costs related to
restructuring programs, and income and losses from investments in equity securities.
1 Net income attributable to Merck & Co., Inc.
2 Merck is providing certain 2025 and 2024 non-GAAP information that excludes certain items because of the nature of these items
and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this
information enhances investors’ understanding of the company’s results because management uses non-GAAP results to assess
performance. Management uses non-GAAP measures internally for planning and forecasting purposes and to measure the
performance of the company along with other metrics. In addition, annual employee compensation, including senior management’s
compensation, is derived in part using a non-GAAP pretax income metric. This information should be considered in addition to, but
not as a substitute for or superior to, information prepared in accordance with GAAP. For a description of the non-GAAP
adjustments, see Table 2a attached to this release.

-- 2 of 13 --

- 3 -
First-Quarter Sales Performance
The following table reflects sales of the company’s top products and significant
performance drivers.
First Quarter
$ in millions 2025 2024 Change
Change Ex-
Exchange Commentary
Total Sales $15,529 $15,775 -2% 1%
Pharmaceutical 13,638 14,006 -3% -1%
Decline driven by vaccines, virology
and immunology, partially offset by
growth in oncology, cardiology and
diabetes.
KEYTRUDA 7,205 6,947 4% 6%
Growth driven by increased global
uptake in earlier-stage indications,
including triple-negative breast
cancer, renal cell carcinoma and non-
small cell lung cancer, as well as
continued strong global demand from
metastatic indications, including
increased uptake in bladder,
endometrial and microsatellite
instability-high (MSI-H) cancers,
partially offset by timing of wholesaler
purchases in the U.S.
GARDASIL/GARDASIL 9 1,327 2,249 -41% -40%
Decline primarily due to lower
demand in China, partially offset by
higher demand in most international
regions, particularly in Japan, as well
as higher pricing and demand in the
U.S. Excluding China, sales grew
14%, or 16% excluding impact of
foreign exchange.
JANUVIA/JANUMET 796 670 19% 21%
Increase primarily due to higher net
pricing in the U.S., partially offset by
lower demand in most international
markets due to ongoing generic
competition, and in the U.S. due to
competitive pressure.
PROQUAD, M-M-R II and
VARIVAX 539 570 -5% -5%
Decrease primarily reflects lower U.S.
sales of PROQUAD that resulted
from borrowing of doses from the
U.S. Centers for Disease Control and
Prevention Pediatric Vaccine
Stockpile, partially offset by higher
U.S. sales of M-M-R II largely
attributable to private-sector buy-in
due to measles outbreaks and higher
pricing.
BRIDION 441 440 - 1%
Relatively flat compared with prior
year, as higher demand and pricing in
the U.S. were offset by lower demand
in several international markets due
to ongoing generic competition.
Lynparza* 312 292 7% 8%
Increase primarily due to higher
demand in the U.S. and certain
international markets.
WINREVAIR 280 - - -
Represents continued uptake since
second-quarter 2024 launch in the
U.S.

-- 3 of 13 --

- 4 -
First Quarter
$ in millions 2025 2024 Change
Change Ex-
Exchange Commentary
Lenvima* 258 255 1% 2%
Increase primarily due to higher
demand in the U.S.
VAXNEUVANCE 230 219 5% 7%
Growth largely driven by higher
demand in Europe and the Asia
Pacific region, partially offset by lower
demand in the U.S. due to
competitive pressure.
PREVYMIS 208 174 19% 22%
Growth primarily due to higher
demand in the U.S.
WELIREG 137 85 62% 63%
Growth primarily driven by higher
demand in the U.S.
CAPVAXIVE 107 - - -
Represents continued uptake since
third-quarter 2024 launch in the U.S.
LAGEVRIO 102 350 -71% -69%
Decline largely driven by lower
demand in the Asia Pacific region,
particularly in Japan.
SIMPONI - 184 -100% -100%
Marketing rights in former Merck
territories reverted to Johnson &
Johnson on Oct. 1, 2024.
Animal Health 1,588 1,511 5% 10%
Growth primarily due to higher
demand for Livestock products, as
well as inclusion of sales from Elanco
aqua business that was acquired in
July 2024.
Livestock 924 850 9% 16%
Growth primarily driven by higher
demand across all species, a benefit
from timing of ruminant product sales,
as well as inclusion of sales from
Elanco aqua business that was
acquired in July 2024.
Companion Animal 664 661 - 3%
Sales consistent with prior year.
Sales of BRAVECTO were $327
million and $332 million in current and
prior year quarters, respectively,
which represents decline of 1%, or
growth of 2% excluding impact of
foreign exchange.
Other Revenues** 303 258 17% 16%
Increase primarily due to higher
payments received for out-licensing
arrangements and higher royalties,
partially offset by lower revenue
from third-party manufacturing
arrangements.
*Alliance revenue for this product represents Merck’s share of profits, which are product sales net of cost of sales and commercialization
costs.
**Other revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate revenues,
including revenue-hedging activities.

-- 4 of 13 --

- 5 -
First-Quarter Expense, EPS and Related Information
The table below presents selected expense information.
$ in millions GAAP
Acquisition-
and
Divestiture-
Related
Costs3
Restructuring
Costs
(Income)
Loss From
Investments
in Equity
Securities
Non-
GAAP2
First Quarter 2025
Cost of sales $3,419 $620 $36 $ - $2,763
Selling, general and administrative 2,552 23 - - 2,529
Research and development 3,621 7 - - 3,614
Restructuring costs 69 - 69 - -
Other (income) expense, net (35) (3) - (107) 75
First Quarter 2024
Cost of sales $3,540 $463 $116 $- $2,961
Selling, general and administrative 2,483 21 5 - 2,457
Research and development 3,992 16 2 - 3,974
Restructuring costs 123 - 123 - -
Other (income) expense, net (33) (4) - (116) 87
GAAP Expense, EPS and Related Information
Gross margin was 78.0% for the first quarter of 2025 compared with 77.6% for the first
quarter of 2024. The increase was primarily due to the favorable impacts of product mix and
lower restructuring costs, partially offset by higher amortization of intangible assets and the
unfavorable impact of foreign exchange.
Selling, general and administrative (SG&A) expenses were $2.6 billion in the first quarter
of 2025, an increase of 3% compared with the first quarter of 2024. The increase was primarily
due to higher administrative and promotional costs, partially offset by the favorable impact of
foreign exchange.
Research and development (R&D) expenses were $3.6 billion in the first quarter of
2025, a decrease of 9% compared with the first quarter of 2024. The decrease was primarily
due to a $656 million charge for the acquisition of Harpoon in the first quarter of 2024 and the
favorable impact of foreign exchange. The decrease was partially offset by a $100 million
charge in the first quarter of 2025 associated with the achievement of a developmental
milestone related to the 2024 acquisition of Eyebiotech Limited (EyeBio), increased
compensation and benefit costs, higher clinical development costs, and increased discovery
research and early drug development costs.
3 Reflects expenses related to business combinations, including the amortization of intangible assets, intangible asset impairment
charges, and expense or income related to changes in the estimated fair value measurement of liabilities for contingent
consideration. Also includes integration, transaction and certain other costs associated with acquisitions and divestitures, as well
as amortization of intangible assets related to collaborations and licensing arrangements.

-- 5 of 13 --

- 6 -
Other (income) expense, net, was $35 million of income in the first quarter of 2025
compared with $33 million of income in the first quarter of 2024.
The effective tax rate was 13.9% for the first quarter of 2025.
GAAP EPS was $2.01 for the first quarter of 2025 compared with $1.87 for the first
quarter of 2024. The increase was primarily driven by a $0.26 per share charge included in the
first quarter of 2024 for the acquisition of Harpoon, partially offset by the unfavorable impact of
foreign exchange.
Non-GAAP Expense, EPS and Related Information
Non-GAAP gross margin was 82.2% for the first quarter of 2025 compared with 81.2%
for the first quarter of 2024. The increase was primarily due to the favorable impact of product
mix, partially offset by the unfavorable impact of foreign exchange.
Non-GAAP SG&A expenses were $2.5 billion in the first quarter of 2025, an increase of
3% compared with the first quarter of 2024. The increase was primarily due to higher
administrative and promotional costs, partially offset by the favorable impact of foreign
exchange.
Non-GAAP R&D expenses were $3.6 billion in the first quarter of 2025, a decrease of
9% compared with the first quarter of 2024. The decrease was primarily due to a $656 million
charge for the acquisition of Harpoon in the first quarter of 2024 and the favorable impact of
foreign exchange. The decrease was partially offset by a $100 million charge in the first quarter
of 2025 associated with the achievement of a developmental milestone related to the 2024
acquisition of EyeBio, increased compensation and benefit costs, higher clinical development
costs, and increased discovery research and early drug development costs.
Non-GAAP other (income) expense, net, was $75 million of expense in the first quarter
of 2025 compared with $87 million of expense in the first quarter of 2024.
The non-GAAP effective tax rate was 14.2% for the first quarter of 2025.
Non-GAAP EPS was $2.22 for the first quarter of 2025 compared with $2.07 for the first
quarter of 2024. The increase was primarily driven by a $0.26 per share charge included in the
first quarter of 2024 for the acquisition of Harpoon, partially offset by the unfavorable impact of
foreign exchange.

-- 6 of 13 --

- 7 -
A reconciliation of GAAP to non-GAAP net income and EPS is provided in the table that
follows.
Pipeline and Portfolio Highlights
In the first quarter, Merck continued to advance its broad and diverse pipeline, achieving
key regulatory and clinical milestones across a range of therapeutic areas.
In oncology, at the European Lung Cancer Congress 2025, Merck presented pivotal data
from the 3475A-D77 Phase 3 trial evaluating the subcutaneous administration of
pembrolizumab with berahyaluronidase alfa (subcutaneous pembrolizumab). Based on these
data, applications for subcutaneous pembrolizumab are under review in the U.S. and Europe; in
the U.S., the Prescription Drug User Fee Act (PDUFA) date is Sept. 23, 2025. If approved,
subcutaneous pembrolizumab has the potential to become a new, meaningful treatment option
that may increase access and save time needed for administration compared to intravenous (IV)
KEYTRUDA. Merck also announced the initiation of waveLINE-010, a Phase 3 trial evaluating a
combination regimen that incorporates zilovertamab vedotin, an investigational antibody-drug
conjugate (ADC) targeting receptor tyrosine kinase-like orphan receptor 1, for the treatment of
patients with previously untreated diffuse large B-cell lymphoma (DLBCL).
Additional regulatory milestones include the U.S. Food and Drug Administration (FDA)
granting Priority Review to Merck’s application for KEYTRUDA plus standard of care as
perioperative treatment for resectable locally advanced head and neck squamous cell
carcinoma (LA-HNSCC), following compelling results from the KEYNOTE-689 trial. The FDA
has set a PDUFA date of June 23, 2025. In addition, Merck received approval from the
European Commission (EC) for KEYTRUDA plus chemotherapy as first-line treatment for adult
patients with unresectable non-epithelioid metastatic malignant pleural mesothelioma, based on
results from the Phase 2/3 IND.227/KEYNOTE-483 trial. The company also received conditional
4 Includes the estimated tax impacts on the reconciling items based on applying the statutory rate of the originating territory of the
non-GAAP adjustments.
First Quarter
$ in millions, except EPS amounts 2025 2024
EPS
GAAP EPS $2.01 $1.87
Difference 0.21 0.20
Non-GAAP EPS that excludes items listed below2 $2.22 $2.07
Net Income
GAAP net income1 $5,079 $4,762
Difference 532 517
Non-GAAP net income that excludes items listed below1,2 $5,611 $5,279
Excluded Items:
Acquisition- and divestiture-related costs3 $647 $496
Restructuring costs 105 246
Income from investments in equity securities (107) (116)
Decrease to net income before taxes 645 626
Estimated income tax (benefit) expense4 (113) (109)
Decrease to net income $532 $517

-- 7 of 13 --

- 8 -
EC approval for two indications for WELIREG, making it the first and only oral hypoxia-inducible
factor-2 alpha inhibitor approved in the European Union, based on results from the Phase 2
LITESPARK-004 and Phase 3 LITESPARK-005 trials.
In vaccines and infectious diseases, Merck received EC approval for CAPVAXIVE for
the prevention of invasive pneumococcal disease and pneumococcal pneumonia in adults,
marking the fourth approval for CAPVAXIVE following the U.S., Canada and Australia. Merck
also received approval for GARDASIL 9 for males in China, making it the first 9-valent HPV
vaccine approved for the prevention of certain HPV-related cancers and diseases in Chinese
males 16-26 years of age. At the 32nd Conference on Retroviruses and Opportunistic
Infections, Merck presented positive results from two pivotal Phase 3 trials of the investigational,
once-daily, oral two-drug regimen of doravirine/islatravir (DOR/ISL) in adults with virologically
suppressed HIV-1 infection. Merck plans to begin submitting applications for marketing
authorization of DOR/ISL by mid-2025.
In cardiovascular disease, results were presented from the Phase 3 ZENITH trial
evaluating WINREVAIR when added to background therapy in adults with pulmonary arterial
hypertension (PAH, Group 1 PH) WHO functional class (FC) III or IV at high risk of mortality.
The results, presented at the American College of Cardiology’s 74th Annual Scientific Session
and Expo, demonstrated that WINREVAIR reduced the risk of a composite of all-cause death,
lung transplantation and hospitalization for PAH by 76% compared to placebo. The trial was
stopped early due to overwhelming efficacy at the interim analysis.
Merck continued executing on its business development strategy to expand and diversify
its pipeline. The company entered into an exclusive license agreement with Jiangsu Hengrui
Pharmaceuticals Co., Ltd. (Hengrui Pharma) for HRS-5346, an investigational oral small
molecule Lipoprotein(a) [Lp(a)] inhibitor currently being evaluated in a Phase 2 clinical trial in
China. The transaction is expected to close in the second quarter of 2025.

-- 8 of 13 --

- 9 -
Notable recent news releases on Merck’s pipeline and portfolio are provided in the table
that follows.
Oncology
FDA Granted Priority Review for Merck’s Application for
KEYTRUDA Plus Standard of Care as Perioperative Treatment
for Resectable LA-HNSCC; Based on Results From Phase 3
KEYNOTE-689 Trial; FDA Set PDUFA Date of June 23, 2025
(Read
Announcement)
WELIREG Received First Conditional EC Approval for Two
Indications; Based on Results From Phase 2 LITESPARK-004
and Phase 3 LITESPARK-005 Trials
(Read
Announcement)
Merck’s Investigational Subcutaneous Pembrolizumab With
Berahyaluronidase Alfa Demonstrated Noninferior
Pharmacokinetics Compared to IV KEYTRUDA in Pivotal 3475A-
D77 Trial; FDA Set PDUFA Date of Sept. 23, 2025
(Read
Announcement)
Merck Announced Phase 3 waveLINE-010 Trial Initiation
Evaluating Zilovertamab Vedotin, an Investigational ADC, for the
Treatment of Patients With Previously Untreated DLBCL
(Read
Announcement)
Vaccines EC Approved CAPVAXIVE for Prevention of Invasive
Pneumococcal Disease and Pneumococcal Pneumonia in Adults
(Read
Announcement)
Cardiovascular
WINREVAIR Reduced Risk of a Composite of All-Cause Death,
Lung Transplantation and Hospitalization for PAH by 76%
Compared to Placebo in Phase 3 ZENITH Trial
(Read
Announcement)
Infectious Diseases
Merck Announced Positive Data From Phase 3 Trials That Show
the Investigational, Once-Daily, Oral Two-Drug Regimen of
Doravirine/Islatravir (DOR/ISL) Maintained HIV-1 Viral
Suppression at Week 48
(Read
Announcement)
Manufacturing and R&D Investment
Merck is making long-term investments in its U.S. manufacturing and R&D capabilities.
Merck has allocated more than $12 billion toward U.S. capital investment since 2018 and
expects to invest over $9 billion more by the end of 2028. This includes the recently announced
opening of a new, $1 billion, 225,000-square-foot facility dedicated to vaccine manufacturing at
Merck’s Durham, North Carolina, site.
Upcoming Investor Event
Merck will host an Oncology Investor Event to coincide with the American Society for
Clinical Oncology Annual Meeting on Monday, June 2, 2025, 6 p.m. CT, at which senior
management will provide an update on the company’s oncology strategy and program. The
event will take place in Chicago and will be accessible via live audio webcast at this weblink.

-- 9 of 13 --

- 10 -
Full-Year 2025 Financial Outlook
The following table summarizes the company’s full-year financial outlook.
Full Year 2025
Updated Prior
Sales* $64.1 billion to $65.6 billion $64.1 billion to $65.6 billion
Non-GAAP Gross margin2 Approximately 82% Approximately 82.5%
Non-GAAP Operating expenses2** $25.6 billion to $26.6 billion $25.4 billion to $26.4 billion
Non-GAAP Other (income) expense, net2 $300 million to $400 million expense $300 million to $400 million expense
Non-GAAP Effective tax rate2 15.5% to 16.5% 16.0% to 17.0%
Non-GAAP EPS2*** $8.82 to $8.97 $8.88 to $9.03
Share count (assuming dilution) Approximately 2.51 billion Approximately 2.53 billion
*The company does not have any non-GAAP adjustments to sales.
**Includes $300 million for an anticipated milestone payment to LaNova Medicines Ltd. (LaNova) associated with the technology transfer for
MK-2010 and an anticipated $200 million upfront payment to Hengrui Pharma upon closing of the license agreement. Outlook does not
assume any additional significant potential business development transactions.
***Includes expected one-time charges of approximately $0.15 per share in the aggregate related to the $300 million payment to LaNova upon
completion of the technology transfer for MK-2010 and the $200 million upfront payment to Hengrui Pharma upon closing of the license
agreement.
Merck has not provided a reconciliation of forward-looking non-GAAP gross margin, non-
GAAP operating expenses, non-GAAP other (income) expense, net, non-GAAP effective tax
rate and non-GAAP EPS to the most directly comparable GAAP measures, given it cannot
predict with reasonable certainty the amounts necessary for such a reconciliation, including
intangible asset impairment charges, legal settlements, and income and losses from
investments in equity securities either owned directly or through ownership interests in
investment funds, without unreasonable effort. These items are inherently difficult to forecast
and could have a significant impact on the company’s future GAAP results.
Merck continues to expect full-year 2025 sales to be between $64.1 billion and $65.6
billion, including a revised negative impact of foreign exchange of approximately 1% at mid-April
2025 exchange rates.
Merck’s outlook includes the impact of tariffs implemented to date by the U.S.
government on imports from other countries, plus the tariffs imposed by foreign governments on
the U.S., the most significant of which relate to China. Merck estimates the impact of these
tariffs will lead to incremental costs of approximately $200 million, which will primarily be
recorded in Cost of Sales, negatively impacting gross margin.
Merck now expects its full-year non-GAAP effective income tax rate to be between
15.5% and 16.5%.
Merck now expects its full-year non-GAAP EPS to be between $8.82 and $8.97,
including a negative impact of foreign exchange of more than $0.20 per share. This revised non-
GAAP EPS range now reflects an anticipated one-time charge of $200 million, or approximately
$0.06 per share, for an upfront payment to be made upon closing of the license agreement with
Hengrui Pharma, which is expected in the second quarter of 2025. If not for this newly
anticipated charge, the updated non-GAAP EPS outlook would have been unchanged from the

-- 10 of 13 --

- 11 -
prior outlook. The guidance range continues to reflect an anticipated one-time charge of $300
million, or approximately $0.09 per share, related to the payment to LaNova that will be
recognized upon completion of the technology transfer for MK-2010. In 2024, non-GAAP EPS of
$7.65 was negatively impacted by a net charge of $1.28 per share related to certain asset
acquisitions, licensing agreements and collaborations.
Consistent with past practice, the financial outlook does not assume additional
significant potential business development transactions.
Earnings Conference Call
Investors, journalists and the general public may access a live audio webcast of the call
on Thursday, April 24, at 9 a.m. ET via this weblink. A replay of the webcast, along with the
sales and earnings news release, supplemental financial disclosures and slides highlighting the
results, will be available at www.merck.com.
All participants may join the call by dialing (800) 369-3351 (U.S. and Canada Toll-Free)
or (517) 308-9448 and using the access code 9818590.
About Merck
At Merck, known as MSD outside of the United States and Canada, we are unified
around our purpose: We use the power of leading-edge science to save and improve lives
around the world. For more than 130 years, we have brought hope to humanity through the
development of important medicines and vaccines. We aspire to be the premier research-
intensive biopharmaceutical company in the world – and today, we are at the forefront of
research to deliver innovative health solutions that advance the prevention and treatment of
diseases in people and animals. We foster a diverse and inclusive global workforce and operate
responsibly every day to enable a safe, sustainable and healthy future for all people and
communities. For more information, visit www.merck.com and connect with us on X (formerly
Twitter), Facebook, Instagram, YouTube and LinkedIn.
Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA
This news release of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes
“forward-looking statements” within the meaning of the safe harbor provisions of the U.S.
Private Securities Litigation Reform Act of 1995. These statements are based upon the current
beliefs and expectations of the company’s management and are subject to significant risks and
uncertainties. There can be no guarantees with respect to pipeline candidates that the
candidates will receive the necessary regulatory approvals or that they will prove to be
commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties
materialize, actual results may differ materially from those set forth in the forward-looking
statements.
Risks and uncertainties include but are not limited to, general industry conditions and
competition; general economic factors, including interest rate and currency exchange rate
fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the
United States and internationally; global trends toward health care cost containment;

-- 11 of 13 --

- 12 -
technological advances, new products and patents attained by competitors; challenges inherent
in new product development, including obtaining regulatory approval; the company’s ability to
accurately predict future market conditions; manufacturing difficulties or delays; financial
instability of international economies and sovereign risk; dependence on the effectiveness of the
company’s patents and other protections for innovative products; and the exposure to litigation,
including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement,
whether as a result of new information, future events or otherwise. Additional factors that could
cause results to differ materially from those described in the forward-looking statements can be
found in the company’s Annual Report on Form 10-K for the year ended December 31, 2024
and the company’s other filings with the Securities and Exchange Commission (SEC) available
at the SEC’s Internet site (www.sec.gov).
Appendix
Generic product names are provided below.
Pharmaceutical
BRIDION (sugammadex)
CAPVAXIVE (Pneumococcal 21-valent Conjugate Vaccine)
GARDASIL (Human Papillomavirus Quadrivalent [Types 6, 11, 16 and 18] Vaccine,
Recombinant)
GARDASIL 9 (Human Papillomavirus 9-valent Vaccine, Recombinant)
JANUMET (sitagliptin and metformin HCl)
JANUVIA (sitagliptin)
KEYTRUDA (pembrolizumab)
LAGEVRIO (molnupiravir)
Lenvima (lenvatinib)
Lynparza (olaparib)
M-M-R II (Measles, Mumps and Rubella Virus Vaccine Live)
PREVYMIS (letermovir)
PROQUAD (Measles, Mumps, Rubella and Varicella Virus Vaccine Live)
SIMPONI (golimumab)
VARIVAX (Varicella Virus Vaccine Live)
VAXNEUVANCE (Pneumococcal 15-valent Conjugate Vaccine)
WELIREG (belzutifan)
WINREVAIR (sotatercept-csrk)
Animal Health
BRAVECTO (fluralaner)
###

-- 12 of 13 --

- 13 -
Media Contacts: Investor Contacts:
Robert Josephson
robert.josephson@merck.com
Michael Levey
michael.levey@merck.com
Peter Dannenbaum
(732) 594-1579
Steven Graziano
(732) 594-1583

-- 13 of 13 --